Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is trading
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(105)
•••
Comment by SunsetGrillon Mar 10, 2021 5:49pm
208 Views
Post# 32765873

RE:RE:RE:RE:RE:RE:This is trading

RE:RE:RE:RE:RE:RE:This is trading Ahhh Whaa? 
Big Phara employee #1 "hey J.R. im gonna spend a few hundred million on a flyer before P3 completed"

Pfizer prez: "here is a blank check I authorize  up to a billion"

P3 fails - Oh well

Doesnt quite work that way in the pharma world

HarveyTwoface wrote: I will definitely stick around with as many shares as possible at these prices because this will easily go 100% - 300% once licensing deal for EU or US are announced. Big Pharma will buy this long before any p3 results. There are still other drugs in ATE pipeline to develop too. Keep your shares because shorting also serves those who are here to accumulate, and you don't know who's buying now at below CAD 5. Price drops? Ok, I pick up more.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities